secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001558370-24-011618
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Q2 net loss narrows to $12.9M; UDENYCA sales up 60% YoY; appoints new CFO
--------------------------------------------------------------------------------

- Q2 2024 net revenue $65.0M (+11% YoY); net loss $12.9M ($0.11 loss per share) vs $42.9M loss in Q2 2023.
- UDENYCA net sales $50.9M (+60% YoY); market share 29% (+4 pts QoQ). LOQTORZI net sales $3.8M in first launch quarter.
- Divestitures of CIMERLI and YUSIMRY generated $177.7M gain in H1 2024; repaid $250M term loan, replaced with $38.7M facility.
- Pipeline: CHS-114 expansion cohorts enrolling; CHS-1000 IND cleared; casdozokitug Phase 2 planned Q4 2024.
- Bryan McMichael appointed CFO, effective Aug 1, 2024; base salary $476K, 50% target bonus, 75,000 stock option grant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024011618/0001558370-24-011618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024011618/chrs-20240807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer